Cell Reports Archives
MicroRNAs in immune cells help protect against metabolic defects in obesity: study
Sep. 5, 2023—Vanderbilt researchers have demonstrated that a cluster of microRNAs — small pieces of RNA that regulate gene expression — work in a type of immune cells called macrophages to help protect against metabolic defects in obesity.
Discovery of “cross-reactive” antibodies could aid treatment of viral co-infections
Feb. 2, 2023— by Bill Snyder More than a million people in the United States are living with HIV, the virus that causes AIDS. One-fifth of them have been co-infected by the hepatitis C virus (HCV), which attacks the liver. Curative drugs for HCV are available, but many people don’t know they’ve been infected. And if they...
Low potassium injures kidney
Jan. 19, 2023—Vanderbilt researchers have discovered that low dietary potassium causes direct kidney injury, suggesting potential new targets for treating chronic kidney disease.
Antibody “fingerprinting” method potential advance to slow spread of dengue
Jan. 12, 2023—Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.
Immune cells drive beta cell loss in Type 2 diabetes
Sep. 8, 2022—Vanderbilt researchers have discovered details of pancreatic beta cell loss — and potential therapeutic targets — during conditions of overnutrition, as occurs in obesity.
Salmonella overcomes host resistance
Jan. 13, 2022—The invading pathogen Salmonella, a common cause of food poisoning, can change its metabolism to overcome host resistance to its colonization.
Molecular imaging of C. diff infection
Sep. 30, 2021—C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection.
“Ultra-potent” antibody against COVID-19 variants isolated at VUMC
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
VUMC antibodies help neutralize two deadly viruses: study
Sep. 8, 2021—Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.
Shared antibodies may push COVID-19 variants: VUMC study
Aug. 10, 2021—Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.
Genetics of hydrocephalus
Jul. 8, 2021—Fluid build-up in the brain — hydrocephalus — increases pressure and risk for brain damage; Vanderbilt researchers have now identified genes and signaling pathways associated with the condition.
Therapeutic antibodies for hantavirus
May. 24, 2021—Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential.
